Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients Multicountry, Multicenter, Observational, Prospective, Primary Data, Real-world Settings
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 291
- 试验地点
- 24
- 主要终点
- Changes from baseline in Asthma Control Questionnaire (ACQ-6)
研究概览
简要总结
This study aims to generate real-world data on the characteristics of patients receiving benralizumab to assess early PRO parameters as well as long-term treatment effects in the Gulf cooperative council (Kingdom of Saudi Arabia, Kuwait, United Arab Emirates, Oman, and Qatar), Latin America (Brazil, Argentina, and Colombia), and India. It is anticipated that the data generated will provide practical, patient-focused real-world evidence and enhance communications between patients and physicians in an objective and structured manner to ensure better disease control in patients under benralizumab treatment.
详细描述
This is a multi-country, multi-center, observational, prospective study involving primary data collection within real-world pulmonary care settings for patients who receive benralizumab treatment for severe uncontrolled eosinophilic asthma.The decision by the physician to start benralizumab is made independently from study inclusion and patient informed consent. Patients will receive benralizumab injections according to the local label in the participating countries (Brazil, Argentina, Colombia, India, and the Gulf cooperative council, including the Kingdom of Saudi Arabia, United Arab Emirates, Kuwait, Oman, and Qatar). No study drug will be provided as part of the study. The entire study period duration will be 56 weeks for each subject. The study is anticipated to run for approximately 18 months and is not anticipated to exceed 24 months. A database soft lock is planned at the end of the initial 8-week period of the study, and one combined descriptive and analytical interim analysis will be performed when 50% of the enrolled subjects complete the 8-week follow-up.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged 18 years or older with a physician's confirmed diagnosis of severe eosinophilic, uncontrolled asthma.
- •Severe uncontrolled eosinophilic asthma requiring high-dose* inhaled corticosteroid plus long-acting β adrenoceptor agonist as maintenance treatment.
- •Patients who have been prescribed but not yet initiated treatment with benralizumab (Fasenra®) according to local approved prescribing information prior to signed informed consent.
- •Provision of the signed written informed consent form (ICF) indicating that they understand the purpose of the study and procedures required for participation.
- •Patients must be able and willing to read and comprehend written instructions and complete the paper PRO questionnaires required by the protocol.
排除标准
- •Clinically important pulmonary diseases other than asthma including chronic obstructive pulmonary disease (as the main diagnosis), bronchiectasis, idiopathic pulmonary fibrosis, pulmonary hypertension, alpha-1-antitrypsin-deficiency, and malignancy of any kind (NB: the following conditions are permitted: nasal polyposis, allergic rhinitis, atopic dermatitis, non-idiopathic pulmonary fibrosis).
- •Currently enrolled in an interventional clinical study except patients being in parallel documented in a national asthma registry
- •An acute or chronic condition that, in the investigator's opinion, would limit the patients' ability to complete questionnaires or participate in this study or impact the interpretations of results.
- •Concurrent biologics for asthma are not allowed. Acceptable wash-out periods for other asthma biologics: ≥30 days from the last dose of the previous biologic.
- •Women who are currently pregnant, breastfeeding, or lactating
结局指标
主要结局
Changes from baseline in Asthma Control Questionnaire (ACQ-6)
时间窗: 8 weeks
The changes from baseline in Asthma Control Questionnaire (ACQ-6) score at eight weeks of benralizumab treatment. Minimum Value - '0' Maximum Value - '6' The lower the value better is the outcome
次要结局
- Changes from baseline in Asthma Control Questionnaire (ACQ-6)(56 weeks)
- Patient global impression of change (PGI-C) response(56 weeks)
- Change from baseline of the patient-reported nasal polyposis symptoms(56 weeks)
- Pre-bronchodilator forced expiratory volume in the first second (FEV1)(56 weeks)
- Percentage of patients with a total score improvement with regards to Minimal clinically important difference in ACQ-6 (Asthma controlled questionnaire)(56 weeks)
- Percentage of patients based on their Asthma control using ACQ-6(56 weeks)
- Pre-bronchodilator forced vital capacity (FVC) changes(56 weeks)
- Patient global impression of severity (PGI-S) response(56 weeks)
- Percentage of patients who achieved 100 ml improvement in their lung function(56 Weeks)